Melbourne-headquartered lung diagnostics technology company 4DMedical (ASX: 4DX) has reached a commercial agreement with medical imaging provider Qscan following a successful pilot program for its products.

The deal represents the first Australian contract to incorporate products from both the pulmonary function and pulmonary structure suites from 4DMedical, including its lung ventilation analysis software (LVAS) that operates on CT (computed tomography) scans.

Qscan a leading provider of diagnostic imaging services in Queensland and has 40 clinics spread across the Sunshine State, NSW, ACT and Tasmania, but the commercial agreement relates specifically to select practices in Brisbane.

"Having completed our pilot with Qscan, we are excited to have progressed to a commercial agreement," says 4DMedical managing director and CEO Dr Andreas Fouras.

"This partnership ensures that more patients and clinicians have access to detailed, actionable insights into lung health, supporting better healthcare outcomes.

"Momentum continues to build with the commercialisation of our technology across the US and Australia. With the addition of Qscan to our network of providers in Australia, I am excited to see our footprint expand to ensure our cutting-edge technology is now becoming more readily available to all Australians."

This represents the fourth deal within two months for 4DMedical which since 25 November has struck commercial contracts with Imaging Partners of Orange County (IPOC) and University of Chicago Medicine in the US, as well as Perth Radiological Clinic (PRC) in Australia.

Earlier this month 4DMedical also received clearance from the US Food and Drug Administration (FDA) for its advanced AI-driven lung diagnostic tool IQ-UIP, which is designed to revolutionise the diagnosis of Usual Interstitial Pneumonia (UIP).

UIP is the hallmark radiological pattern for diagnosing Interstitial Pulmonary Fibrosis (IPF), a rare yet severe condition characterised by chronic inflammation and progressive lung fibrosis, with median survival rates of one to two years for sufferers. The condition affects 140,000 individuals annually in the United States alone, with over 50,000 new cases diagnosed each year.

Diagnosing UIP poses a significant clinical challenge due to its nonspecific symptomatology, often mimicking more prevalent respiratory conditions like COPD, bronchitis, or asthma. 

In other US news, last week the company won a contract to supply its CT Ventilation-Perfusion (CT:VQ) scans to the United States Department of Defense (DoD) as a paid pilot, ahead of an FDA submission for the product.

The contract builds on an earlier agreement with the DoD for the deployment of its CT LVAS offering in a clinical pilot program.

4DX shares were up 6.19 per cent at $0.60 in early trading.

Help us deliver quality journalism to you.As a free and independent news site providing daily updates during a period of unprecedented challenges for businesses everywherewe call on your support